Carlos Zúñiga-Ramírez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carlos Zúñiga-Ramírez has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Gomez-Figueroa
Neurology Department, Civil Hospital of Guadalajara , Guadalajara, Jalisco 44280
4 shared publications - Leonel Villa-Villegas
Movement Disorders and Neurodegenerative Diseases Unit, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
4 shared publications - Alfonso Fasano
Department of Biomedical Sciences Humanitas University Milan Italy
3 shared publications Carlos Eduardo Piña-Avilés
Department of Genetics, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
3 shared publications- Katia Carmina Farías-Moreno
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Movement Disorders and Neurodegenerative Diseases Unit, Guadalajara, Jalisco, México
3 shared publications - Luz Gabriela Lira-Jaime
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Movement Disorders and Neurodegenerative Diseases Unit, Guadalajara, Jalisco, México
3 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6)
Cerebrotendinous Xanthomatosis
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6)
Cerebrotendinous Xanthomatosis
- 12 September 2026
- Published by Springer Nature
- p. 555-565
LLM-Guided Refinement of Clinical Instruments: A Reproducible Framework with Expert Validation
- 12 September 2026
- Published by Springer Nature
- p. 555-565
LLM-Guided Refinement of Clinical Instruments: A Reproducible Framework with Expert Validation
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000132
Association Between Ultrasound Diaphragmatic Measurements and Mechanical Ventilation in Patients With Guillain-Barré Syndrome
Background and ObjectivesRespiratory failure is a serious complication in Guillain-Barré syndrome (GBS). Traditional clinical scales have limitations in accurately predicting the need for invasive ...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000132
Open AccessAssociation Between Ultrasound Diaphragmatic Measurements and Mechanical Ventilation in Patients With Guillain-Barré Syndrome
Background and ObjectivesRespiratory failure is a serious complication in Guillain-Barré syndrome (GBS). Traditional clinical scales have limitations in accurately predicting the need for invasive ...
- Open Access
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (10) , 001-008
Epidemiology and clinical features of movement disorders in a Mexican Mestizo cohort: a 10-year tertiary-center study
Movement disorders comprise a heterogeneous spectrum of neurological conditions characterized by impaired motor control. Limited epidemiological data exist for Latin American populations, particularly for Mexican Mestizos. To characterize the epidemiological profile and clinical features of movement disorders in a large cohort of Mexican Mestizo patients evaluated at a public tertiary referral center in western Mexico. We conducted a 10-year retrospective cohort study (2012–2022) analyzing medical records from the Movement Disorders and Neurodegenerative Diseases Unit at the Hospital Civil de Guadalajara, a public tertiary university hospital from the western region of Mexico. Inclusion criteria were confirmed movement disorder diagnosis and a minimum of two clinical evaluations. Binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs). Among 1,830 records (mean age 58.5 ± 17.0 years, 53.9% female, all self-identified as Mexican Mestizo), hypokinetic disorders comprised 63.9% (n = 1,170) and hyperkinetic disorders 36.1% (n = 660). Parkinsonism (63.6%, n = 1,163) and tremor (11.3%, n = 206) were the most frequent subtypes. Hypokinetic disorders were associated with older age (64.2 ± 12.8 vs. 48.5 ± 18.9 years, p < 0.001), hypertension (OR = 2.29; 1.78–2.95; p = 0.001), and smoking (OR = 1.51; 1.13–2.03; p = 0.005). Hyperkinetic disorders were associated with male sex (OR = 1.47; 1.19–1.82; p < 0.001), family history (OR = 1.92; 1.49–2.47; p < 0.001), and functional presentations (OR = 11.0; 5.53–22.14; p < 0.001). This is the largest reported Mexican Mestizo cohort with movement disorders evaluated in a single public tertiary center. Findings reveal distinct demographic and clinical patterns and may inform integrated cardiovascular–neurological care models, screening protocols, and resource allocation within the Mexican public health system.
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (10) , 001-008
Open AccessEpidemiology and clinical features of movement disorders in a Mexican Mestizo cohort: a 10-year tertiary-center study
Movement disorders comprise a heterogeneous spectrum of neurological conditions characterized by impaired motor control. Limited epidemiological data exist for Latin American populations, particularly for Mexican Mestizos. To characterize the epidemiological profile and clinical features of movement disorders in a large cohort of Mexican Mestizo patients evaluated at a public tertiary referral center in western Mexico. We conducted a 10-year retrospective cohort study (2012–2022) analyzing medical records from the Movement Disorders and Neurodegenerative Diseases Unit at the Hospital Civil de Guadalajara, a public tertiary university hospital from the western region of Mexico. Inclusion criteria were confirmed movement disorder diagnosis and a minimum of two clinical evaluations. Binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs). Among 1,830 records (mean age 58.5 ± 17.0 years, 53.9% female, all self-identified as Mexican Mestizo), hypokinetic disorders comprised 63.9% (n = 1,170) and hyperkinetic disorders 36.1% (n = 660). Parkinsonism (63.6%, n = 1,163) and tremor (11.3%, n = 206) were the most frequent subtypes. Hypokinetic disorders were associated with older age (64.2 ± 12.8 vs. 48.5 ± 18.9 years, p < 0.001), hypertension (OR = 2.29; 1.78–2.95; p = 0.001), and smoking (OR = 1.51; 1.13–2.03; p = 0.005). Hyperkinetic disorders were associated with male sex (OR = 1.47; 1.19–1.82; p < 0.001), family history (OR = 1.92; 1.49–2.47; p < 0.001), and functional presentations (OR = 11.0; 5.53–22.14; p < 0.001). This is the largest reported Mexican Mestizo cohort with movement disorders evaluated in a single public tertiary center. Findings reveal distinct demographic and clinical patterns and may inform integrated cardiovascular–neurological care models, screening protocols, and resource allocation within the Mexican public health system.
- Open Access
- 5 September 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
“Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report”
Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline. Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor. Deep brain stimulation (DBS) might be effective for motor symptoms. Choosing the best DBS target is essential for successful treatment. Case reports and Clinical Solution: Two subjects with a predominant tremorous syndrome due to POLR3A gene mutation with no response to pharmacological treatment underwent DBS at ventral intermediate nuclei (Vim DBS) of thalamus, with significant improvement in tremor. Gap in Knowledge: Tremor in POLR3A gene mutation could respond to Vim DBS.
- 5 September 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1)
Open Access“Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report”
Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline. Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor. Deep brain stimulation (DBS) might be effective for motor symptoms. Choosing the best DBS target is essential for successful treatment. Case reports and Clinical Solution: Two subjects with a predominant tremorous syndrome due to POLR3A gene mutation with no response to pharmacological treatment underwent DBS at ventral intermediate nuclei (Vim DBS) of thalamus, with significant improvement in tremor. Gap in Knowledge: Tremor in POLR3A gene mutation could respond to Vim DBS.
- Open Access
- 22 July 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 32
Deep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant
Clinical vignette: Leigh syndrome (LS) and Leigh-like syndromes (LLS), now collectively referred to as Leigh Syndrome Spectrum (LSS), encompass a wide range of clinical manifestations, including epilepsy, neurodevelopmental delay, and movement disorders such as ataxia, chorea, and dystonia. Although rare, LSS can present atypical symptoms in certain cases. The primary etiological cause of LSS is genetic, resulting from mitochondrial alterations. Clinical dilemma: Hyperkinesias in LSS or other mitochondrial disorders can be disabling, leading to a significant reduction in the patient’s quality of life. Clinical solution: Globus pallidum deep brain stimulation (GPi-DBS) surgery is an effective treatment for hyperkinesias, such as chorea, and dystonia, caused by mitochondrial defects. Gap in knowledge: Pathogenic DNM1-related mitochondrial disorders with Leigh syndrome phenotype may show long-term improvement of hyperkinetic movements after GPi-DBS.
- 22 July 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 32
Open AccessDeep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant
Clinical vignette: Leigh syndrome (LS) and Leigh-like syndromes (LLS), now collectively referred to as Leigh Syndrome Spectrum (LSS), encompass a wide range of clinical manifestations, including epilepsy, neurodevelopmental delay, and movement disorders such as ataxia, chorea, and dystonia. Although rare, LSS can present atypical symptoms in certain cases. The primary etiological cause of LSS is genetic, resulting from mitochondrial alterations. Clinical dilemma: Hyperkinesias in LSS or other mitochondrial disorders can be disabling, leading to a significant reduction in the patient’s quality of life. Clinical solution: Globus pallidum deep brain stimulation (GPi-DBS) surgery is an effective treatment for hyperkinesias, such as chorea, and dystonia, caused by mitochondrial defects. Gap in knowledge: Pathogenic DNM1-related mitochondrial disorders with Leigh syndrome phenotype may show long-term improvement of hyperkinetic movements after GPi-DBS.
- Open Access
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-011
The costs and benefits of deep brain stimulation in Parkinson's disease: a review and social network analysis
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Levodopa has been considered the best treatment option. However, deep brain stimulation (DBS) use has increased over time, mostly when levodopa-related complications arise.To review the current evidence regarding economic evaluations assessing costs and benefits comparing pharmacological versus surgical treatment among subjects with PD.We searched three databases (PubMed, Embase, and Google Scholar) for studies comparing levodopa treatment and DBS among subjects with PD in terms of costs and benefits from therapy.Out of the 107 studies identified, 14 met the inclusion criteria. Most of the published studies were from Europe. Incremental cost-effectiveness ratios have shown variable results, from -€979 to €6,729 per change of 1 point in the score on part III of the Unified Parkinson's Disease Rating Scale (UPDRS III), while incremental cost-utility ratios depict values as low as €6,700 and as high as $704,906.03 per quality-adjusted life-years (QALY).We observed a higher cost during the 1st year of DBS implantation due to the surgical procedure itself, subsequently, there was a trend for a lower cost over the following years, with no loss of benefit. Overall, the studies showed DBS as a cost-effective measure at 5-years after implantation.
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-011
Open AccessThe costs and benefits of deep brain stimulation in Parkinson's disease: a review and social network analysis
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Levodopa has been considered the best treatment option. However, deep brain stimulation (DBS) use has increased over time, mostly when levodopa-related complications arise.To review the current evidence regarding economic evaluations assessing costs and benefits comparing pharmacological versus surgical treatment among subjects with PD.We searched three databases (PubMed, Embase, and Google Scholar) for studies comparing levodopa treatment and DBS among subjects with PD in terms of costs and benefits from therapy.Out of the 107 studies identified, 14 met the inclusion criteria. Most of the published studies were from Europe. Incremental cost-effectiveness ratios have shown variable results, from -€979 to €6,729 per change of 1 point in the score on part III of the Unified Parkinson's Disease Rating Scale (UPDRS III), while incremental cost-utility ratios depict values as low as €6,700 and as high as $704,906.03 per quality-adjusted life-years (QALY).We observed a higher cost during the 1st year of DBS implantation due to the surgical procedure itself, subsequently, there was a trend for a lower cost over the following years, with no loss of benefit. Overall, the studies showed DBS as a cost-effective measure at 5-years after implantation.
- 10 September 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (5) , e209778
Contribution of Stroke to Long-Term All-Cause and Cause-Specific Mortality in Mexico City
Stroke mortality is more common in low-income and middle-income nations such as Mexico. Prognosis data typically rely on short-term hospital follow-ups, revealing high mortality rates due to systemic complications and early recurrence. We aim to explore stroke's long-term impact by examining all-cause and cause-specific mortality. We analyzed data from the Mexico City Prospective Study (1998-2004) with known mortality outcomes until December 2022. Baseline variables were compared between participants who had stroke and nonstroke participants. Cox proportional hazard regression assessed each variable's contribution to overall mortality. Subsequent analysis within the stroke subgroup aimed to identify unique risk factors of mortality, using Cox regression models adjusted for age, sex, and time since stroke. Among 145,537 eligible participants, 1,492 (1.0%) had a history of stroke. Participants who had stroke were older (57.58 vs 50.16, p < 0.001); had lower mean weekly income ($108.24 vs $176.14, p < 0.001); had higher alcohol intake and smoking frequency; and had more frequent comorbidities such as hypertension (48.9 vs 19.3%, p < 0.001), diabetes (23.4 vs 12.9%, p < 0.001), and ischemic heart disease (5.4 vs 1.0%, p < 0.001). They had a significantly increased risk of death from any cause (hazard ratio [HR] 2.59, 95% CI 2.37-2.83, p < 0.001). Deceased participants with stroke were more likely to be male, with a higher prevalence of diabetes, hypertension, and abnormal waist-hip index. Stroke increased the risk of death from cardiac (HR 3.56, 95% CI 3.02-4.19, p < 0.001), renal (HR 2.05, 95% CI 1.58-2.66, p < 0.001), and pulmonary (HR 2.29, 95% CI 1.79-2.92, p < 0.001) causes. This study confirms stroke's association with higher mortality rates, especially from cardiac, renal, and pulmonary causes in Mexico. It underscores the elevated prevalence of cardiovascular comorbidities and adverse socioeconomic profiles among participants who had stroke and those who died with a history of stroke.
- 10 September 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (5) , e209778
Contribution of Stroke to Long-Term All-Cause and Cause-Specific Mortality in Mexico City
Stroke mortality is more common in low-income and middle-income nations such as Mexico. Prognosis data typically rely on short-term hospital follow-ups, revealing high mortality rates due to systemic complications and early recurrence. We aim to explore stroke's long-term impact by examining all-cause and cause-specific mortality. We analyzed data from the Mexico City Prospective Study (1998-2004) with known mortality outcomes until December 2022. Baseline variables were compared between participants who had stroke and nonstroke participants. Cox proportional hazard regression assessed each variable's contribution to overall mortality. Subsequent analysis within the stroke subgroup aimed to identify unique risk factors of mortality, using Cox regression models adjusted for age, sex, and time since stroke. Among 145,537 eligible participants, 1,492 (1.0%) had a history of stroke. Participants who had stroke were older (57.58 vs 50.16, p < 0.001); had lower mean weekly income ($108.24 vs $176.14, p < 0.001); had higher alcohol intake and smoking frequency; and had more frequent comorbidities such as hypertension (48.9 vs 19.3%, p < 0.001), diabetes (23.4 vs 12.9%, p < 0.001), and ischemic heart disease (5.4 vs 1.0%, p < 0.001). They had a significantly increased risk of death from any cause (hazard ratio [HR] 2.59, 95% CI 2.37-2.83, p < 0.001). Deceased participants with stroke were more likely to be male, with a higher prevalence of diabetes, hypertension, and abnormal waist-hip index. Stroke increased the risk of death from cardiac (HR 3.56, 95% CI 3.02-4.19, p < 0.001), renal (HR 2.05, 95% CI 1.58-2.66, p < 0.001), and pulmonary (HR 2.29, 95% CI 1.79-2.92, p < 0.001) causes. This study confirms stroke's association with higher mortality rates, especially from cardiac, renal, and pulmonary causes in Mexico. It underscores the elevated prevalence of cardiovascular comorbidities and adverse socioeconomic profiles among participants who had stroke and those who died with a history of stroke.
- Open Access
- 9 May 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1385945
Clinical predictors for mechanical ventilation assistance in Guillain-Barré syndrome
Background: Guillain-Barré syndrome (GBS) frequently leads to respiratory failure and autonomic dysfunction, resulting in approximately one-third of patients requiring mechanical ventilation.Objective: This study aimed to identify clinical predictors for mechanical ventilation in patients with GBS.Methods: This research was conducted from 2010 to 2021 using registries from a tertiary hospital in an upper middle-income Latin American country. Participants were categorized into two groups based on their ventilation status. Demographic data were collected, and independent predictors of the need for mechanical ventilation were determined through multivariate logistic regression analysis.Results: Dysautonomic events occurred in 36% of the patients, with 17% requiring mechanical ventilation; the average duration of intubation was 1.16 ± 3.18 days. The multivariate analysis indicated that bulbar dysfunction significantly increased the likelihood of requiring mechanical ventilation by 19-fold (OR 18.67, 95% CI 5.85–59.42), followed by ophthalmoplegia, which increased the likelihood by sixfold (OR 5.68, 95% CI 1.28–25.19).Conclusion: Bulbar dysfunction, dysautonomia, and lower Medical Research Council (MRC) scores were significant predictors of the need for mechanical ventilation in hospitalized GBS patients. These findings support the need for close monitoring and early admission to the intensive care unit (ICU) admission for at-risk patients.
- 9 May 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1385945
Open AccessClinical predictors for mechanical ventilation assistance in Guillain-Barré syndrome
Background: Guillain-Barré syndrome (GBS) frequently leads to respiratory failure and autonomic dysfunction, resulting in approximately one-third of patients requiring mechanical ventilation.Objective: This study aimed to identify clinical predictors for mechanical ventilation in patients with GBS.Methods: This research was conducted from 2010 to 2021 using registries from a tertiary hospital in an upper middle-income Latin American country. Participants were categorized into two groups based on their ventilation status. Demographic data were collected, and independent predictors of the need for mechanical ventilation were determined through multivariate logistic regression analysis.Results: Dysautonomic events occurred in 36% of the patients, with 17% requiring mechanical ventilation; the average duration of intubation was 1.16 ± 3.18 days. The multivariate analysis indicated that bulbar dysfunction significantly increased the likelihood of requiring mechanical ventilation by 19-fold (OR 18.67, 95% CI 5.85–59.42), followed by ophthalmoplegia, which increased the likelihood by sixfold (OR 5.68, 95% CI 1.28–25.19).Conclusion: Bulbar dysfunction, dysautonomia, and lower Medical Research Council (MRC) scores were significant predictors of the need for mechanical ventilation in hospitalized GBS patients. These findings support the need for close monitoring and early admission to the intensive care unit (ICU) admission for at-risk patients.
- 24 August 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (S3) , S41-S44
Ataxia due to a COQ8A Novel Variant in Primary Coenzyme Q10 Deficiency
- 24 August 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (S3) , S41-S44
Ataxia due to a COQ8A Novel Variant in Primary Coenzyme Q10 Deficiency